Current Approaches in the Management of Monoclonal Gammopathies: an approach to Waldenström Macroglobulinemia
Main Article Content
Abstract
Monoclonal gammopathies encompass a spectrum of disorders characterized by the abnormal proliferation of plasma cells, leading to the production of monoclonal immunoglobulins. Waldenström macroglobulinemia (WM) is a rare, indolent lymphoproliferative disorder characterized by the presence of an IgM monoclonal gammopathy, bone marrow infiltration by lymphoplasmacytic cells, and clinical features such as hyperviscosity, lymphadenopathy, and hepatosplenomegaly. Recent advances in understanding the pathogenesis of WM have led to the development of novel therapeutic strategies, including targeted therapies and immunomodulatory agents, which have significantly improved outcomes for patients. This article provides an overview of the current understanding of WM pathophysiology, clinical presentation, diagnostic approach, and recent advancements in its management.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. (2009). Screening panels for detection of monoclonal gammopathies. clinical chemistry, 55(8), 1517-1522.
https://doi.org/10.1373/clinchem.2009.126664
II. (2016). Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. clinical chemistry and laboratory medicine (cclm), 54(6). https://doi.org/10.1515/cclm-2015-0580
III. (2004). Lymphoma and peripheral neuropathy: a clinical review. muscle & nerve, 31(3), 301-313. https://doi.org/10.1002/mus.20163
IV. (2013). Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. a systematic review. haematologica, 98(7), 1003-1013. https://doi.org/10.3324/haematol.2012.083386
V. (2011). Temporal and geographic variations of waldenstrom macroglobulinemia incidence. cancer, 118(15), 3793-3800.
https://doi.org/10.1002/cncr.26627
VI. (2010). Diagnosis and management of waldenström macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (msmart) guidelines. mayo clinic proceedings, 85(9), 824-833.
https://doi.org/10.4065/mcp.2010.0304
VII. (2005). Diagnosis and management of waldenstrom's macroglobulinemia. journal of clinical oncology, 23(7), 1564-1577.
https://doi.org/10.1200/jco.2005.03.144
VIII. (2017). Diagnosis and management of waldenström macroglobulinemia. jama oncology, 3(9), 1257. https://doi.org/10.1001/jamaoncol.2016.5763
IX. (2017). Bing-neel syndrome: illustrative cases and comprehensive review of the literature. mediterranean journal of hematology and infectious diseases, 9(1), e2017061.
https://doi.org/10.4084/mjhid.2017.061
X. (2016). Optimizing therapy for nodal marginal zone lymphoma. blood, 127(17), 2064-2071.
https://doi.org/10.1182/blood-2015-12-624296
XI. (2010). Igm multiple myeloma: disease definition, prognosis, and differentiation from waldenstrom's macroglobulinemia. american journal of hematology, 85(11), 853-855.
https://doi.org/10.1002/ajh.21845
XII. (2017). Monoclonal igm gammopathy and waldenström’s macroglobulinemia. deutsches ärzteblatt international.
https://doi.org/10.3238/arztebl.2017.0745
XIII. (2006). Monoclonal gammopathy of undetermined significance, waldenström macroglobulinemia, al amyloidosis, and related plasma cell disorders: diagnosis and treatment. mayo clinic proceedings, 81(5), 693-703. https://doi.org/10.4065/81.5.693
XIV. (2005). Prognostic validation of the international classification of immunoglobulin m gammopathies: a survival advantage for patients with immunoglobulin m monoclonal gammopathy of undetermined significance?. clinical cancer research, 11(5), 1786-1790.
https://doi.org/10.1158/1078-0432.ccr-04-1899
XV. (1995). Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. annals of neurology, 37(S1), 32-42.
https://doi.org/10.1002/ana.410370705
XVI. (2022). Diagnostics in waldenström’s macroglobulinemia: a consensus statement of the european consortium for waldenström’s macroglobulinemia. leukemia, 37(2), 388-395. https://doi.org/10.1038/s41375-022-01762-3
XVII. (2020). Younger patients with waldenström macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. american journal of hematology, 95(12), 1473-1478.
https://doi.org/10.1002/ajh.25961
XVIII. (2005). Lymphoplasmacytic lymphoma/ waldenstrom macroglobulinemia. advances in anatomic pathology, 12(5), 246-255. https://doi.org/10.1097/01.pap.0000184176.65919.17
XIX. (2018). Serum markers in the differential diagnosis of waldenstrom macroglobulinemia and other igm monoclonal gammopathies. journal of clinical laboratory analysis, 33(3).
https://doi.org/10.1002/jcla.22827
XX. (2018). Kidney involvement of patients with waldenström macroglobulinemia and other igm-producing b cell lymphoproliferative disorders. clinical journal of the american society of nephrology, 13(7), 1037-1046.
https://doi.org/10.2215/cjn.13041117
XXI. (2005). Immunoglobulin m monoclonal gammopathies of undetermined significance and indolent waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. journal of clinical oncology, 23(21), 4662-4668. https://doi.org/10.1200/jco.2005.06.147
XXII. (2023). Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. american journal of hematology, 98(2), 348-358. https://doi.org/10.1002/ajh.26796
XXIII. (2023). Comparision of the diagnostic sensitivity of biochemical tests in the screening of monoclonal gammopathy. international journal of clinical biochemistry and research, 10(1), 96-100. https://doi.org/10.18231/j.ijcbr.2023.015
XXIV. (2021). Hyperviscosity-related retinopathy and serous macular detachment in waldenström’s macroglobulinemia: a mortal case in 5 years. european journal of ophthalmology, 32(4), NP109-NP114. https://doi.org/10.1177/11206721211002066
XXV. (2023). Diagnosing, imaging, and successfully treating a debilitating case of bing–neel syndrome: a multidisciplinary feat. clinical case reports, 11(5). https://doi.org/10.1002/ccr3.7296
XXVI. (2023). Marginal zone lymphoma: 2023 update on diagnosis and management. american journal of hematology, 98(10), 1645-1657.
https://doi.org/10.1002/ajh.27058
XXVII. (2020). A rare case of synchronous waldenström’s macroglobulinemia and cutaneous squamous cell carcinoma with a lung mass: a diagnostic and management dilemma. case reports in oncology, 13(3), 1474-1482.
https://doi.org/10.1159/000511460
XXVIII. (2002). Cast nephropathy in a case of waldenström’s macroglobulinemia. nephron, 91(3), 512-515. https://doi.org/10.1159/000064299
XXIX. [29] (2019). An unusual presentation of a rare neoplasm - waldenstrom’s macroglobulinemia. tropical journal of pathology and microbiology, 5(10), 822-826.
https://doi.org/10.17511/jopm.2019.i10.11
XXX. (2021). Eha endorsement of esmo clinical practice guidelines for diagnosis, treatment, and follow-up for waldenström’s macroglobulinemia. hemasphere, 5(10), e634.
https://doi.org/10.1097/hs9.0000000000000634
XXXI. (2023). Waldenström macroglobulinemia: diagnosis and treatment. hematologia.
https://doi.org/10.5603/hcp.a2022.0014
XXXII. (2009). Simultaneously significant hepatic and mild splenic uptake of tc-99m mdp resulting from waldenstrom macroglobulinemia. clinical nuclear medicine, 34(7), 441-442.
https://doi.org/10.1097/rlu.0b013e3181a7d0a3
XXXIII. (2017). Diffuse large b‐cell lymphoma mimicking cardiac amyloidosis. clinical case reports, 5(6), 1034-1035. https://doi.org/10.1002/ccr3.948
XXXIV. (2014). A paroxysmal nocturnal haemoglobinuria progress with waldenström macroglobulinemia along with t cell monoclonal expansion. indian journal of hematology and blood transfusion, 30(S1), 227-231. https://doi.org/10.1007/s12288-014-0337-9